SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, and Genentech, a member of the Roche Group, announced a global licensing agreement on February 2nd, 2026. In a deal valued at over $1.5 billion, Genentech will receive exclusive worldwide rights to develop and commercialize an undisclosed program based on SanegeneBio’s proprietary RNAi platform.

According to a press release issued by SanegeneBio, the RNAi platform includes novel chemistries and delivery technologies that can be used to develop siRNA medicines in various disease areas. SanegeneBio will lead program development until an unspecified point early in the development process, upon which Genentech will assume responsibility for further clinical development as well as commercialization activities.

“Entering into this agreement with Genentech marks another important milestone for our innovative and differentiated RNAi chemistry and delivery platforms,” said Weimin Wang, Ph.D., CEO and Founder, SanegeneBio, in the release. “We are delighted to work with a global scientific leader to continue delivering effective and life-changing therapies for patients worldwide.”

According to the release, SanegeneBio will receive a $200 million upfront payment for the exclusive license. SanegeneBio is also eligible for various development and commercialization milestones that can raise that total to approximately $1.5 billion, as well as tiered royalties on any products derived from the collaboration.